HPLC method for the determination of fluvoxamine in human plasma and urine for application to pharmacokinetic studies


Ulu S. T.

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, cilt.43, ss.1444-1451, 2007 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 43 Konu: 4
  • Basım Tarihi: 2007
  • Doi Numarası: 10.1016/j.jpba.2006.11.005
  • Dergi Adı: JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
  • Sayfa Sayıları: ss.1444-1451

Özet

A simple, specific and sensitive high-performance liquid chromatographic (HPLC) method has been developed for the assay of fluvoxamine in human plasma and urine. The method was based on reaction of fluvoxamine with 1,2-naphthoquinone-4-sulphonic acid sodium salt (NQS) forming orange colored product. The fluvoxamine-NQ derivative was separated by isocratic reversed-phase HPLC and detected at 450 run. The chromatographic conditions were as follows: Phenomenex C-18 (250 mm x 4.6 mm i.d., 5 mu m) column, mobile phase consisting of acetonitrile/water (80:20 v/v) at a flow rate of 1 ml/min. Tryptamine was selected as an internal standard. The assay was linear over the concentration range of 5-145 and 2-100 ng/ml for plasma and urine, respectively. The limits of detection (LOD) were 1.4 and I ng/ml for plasma and urine estimation at a signal-to-noise (S/N) ratio of 3. The limits of quantification (LOQ) were 5 and 2 ng/ml for plasma and urine, respectively. The extraction recoveries were found to be 96.66 +/- 0.69 and 96.73 +/- 2.17% for plasma and urine, respectively. The intra-day and inter-day standard deviations (S.D.) were less than 1. The method indicated good performance in terms of specificity, linearity, detection and quantification limits, precision and accuracy. This assay was demonstrated to be applicable for clinical pharmacokinetic studies. (c) 2006 Elsevier B.V. All rights reserved.